Back
Open Access

Icosapent ethyl: what are the most likely mechanisms of benefit?

Session: Cardiovascular risk reduction beyond statin therapy: exploring the role of icosapent ethyl
Topic: Treatment
Speaker: Professor C. Packard (Glasgow, GB)
Sponsored by PACE-CME – Supported by an unrestricted educational grant from Amarin Pharma
Event: ESC Preventive Cardiology 2022

Congress Presentation

Add to my library

Like

About the speaker

Professor Chris Packard

Glasgow (United Kingdom of Great Britain & Northern Ireland)
7 presentations
0 follower

4 more presentations in this session

Introduction.

Speaker: Professor U. Laufs (Leipzig, DE)

Access
Slides
Like
Thumbnail

Assessing residual cardiovascular risk in patients already treated with statin therapy.

Speaker: Professor A. Zambon (Padua, IT)

Access
Video
Like
Thumbnail

Exploring the role of icosapent ethyl based on current clinical evidence.

Speaker: Professor J. Jukema (Leiden, NL)

Access
Video
Like
Thumbnail

Discussion.

Access
Like
Thumbnail

Access the full session

Cardiovascular risk reduction beyond statin therapy: exploring the role of icosapent ethyl

Speakers: Professor C. Packard, Professor U. Laufs, Professor A. Zambon, Professor J. Jukema
Access
Video
Like
Thumbnail

About the event

Image

ESC Preventive Cardiology 2022

7 April - 9 April 2022

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

bristol-myers-squibb Explore sponsored resources
novartis Explore sponsored resources